EPM2A (Laforin Isoform a, Epilepsy, Progressive Myoclonus type 2A Lafora disease (laforin), Epilepsy Progressive myoclonus type 2 Lafora disease (laforin), LDE, LD)

Epilepsy, progressive myoclonus type 2A (EPM2A), also known as laforin, is a dual-specificity phosphatase that associates with polyribosomes. The protein may be involved in the control of glycogen metabolism, particularly in monitoring for and preventing the formation of poorly branched glycogen molecules. Defects in EPM2A are a cause of progressive myoclonic epilepsy type 2(EPM2), also known as Lafora disease. EPM2 is an autosomal recessive and severe form of adolescent-onset progressive epilepsy.||Applications: |Suitable for use in ELISA, Western Blot. Other applications not tested.||Recommended Dilution:|Western Blot: 1:1000-2000 |Optimal dilutions to be determined by the researcher.||Hybridoma: |FO myeloma cells with spleen cells from Balb/c mice. ||Storage and Stability:|May be stored at 4°C for short-term only. Aliquot to avoid repeated freezing and thawing. Store at -20°C. Aliquots are stable for 12 months. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.